Modulation of Adjuvant 5-FU by Folinic Acid and Interferon-alpha in Colon Cancer

• Status: Completed
• Trial end date: 2009-07-01

Summary

The primary objective was to improve adjuvant 5-FU chemoradiotherapy in resectable rectal cancer. The investigators hypothesis was that modulation of 5-FU by addition of either FA or INF-alpha may increase overall survival.

• Phase: Phase 3

Details

• Lead Sponsor: University of Ulm
• Collaborators: Medac GmbH (Hamburg, Germany); Roche (Grenzach-Wyhlen, Germany)
• Treatments: Fluorouracil; Folic Acid; Interferon-alpha; Interferons; Leucovorin; Levoleucovorin